These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 1363408)

  • 1. Oro-caecal transit time in man assessed by the sulfasalazine/sulfapyridine test. Correlation between plasma-saliva appearance of sulfapyridine.
    Dhôte R; Leglise P; Bergmann JF; Conort O; Caulin C
    Fundam Clin Pharmacol; 1992; 6(8-9):383-5. PubMed ID: 1363408
    [No Abstract]   [Full Text] [Related]  

  • 2. Orocecal transit time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine intake.
    Dhôte R; Bergmann JF; Leglise P; Chassany O; Elkharrat D; Conort O; Caulin C
    Clin Pharmacol Ther; 1995 Apr; 57(4):461-70. PubMed ID: 7712676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfapyridine appearance in plasma after salicylazosulfapyridine. Another simple measure of intestinal transit.
    Kellow JE; Borody TJ; Phillips SF; Haddad AC; Brown ML
    Gastroenterology; 1986 Aug; 91(2):396-400. PubMed ID: 2873075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary excretion and pharmacokinetics of sulfapyridine after sulfasalazine.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Clin Pharmacol Ther; 1977 Dec; 22(6):917-27. PubMed ID: 21768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
    Day JM; Houston JB
    Br J Clin Pharmacol; 1980 Jan; 9(1):91-4. PubMed ID: 6101957
    [No Abstract]   [Full Text] [Related]  

  • 6. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
    Bates TR; Blumenthal HP; Pieniaszek HJ
    Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative systemic availability of sulfapyridine from commercial enteric-coated and uncoated sulfasalazine tablets.
    Pieniaszek HJ; Resetarits DE; Wilferth WW; Blumenthal HP; Bates TR
    J Clin Pharmacol; 1979 Jan; 19(1):39-45. PubMed ID: 33201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chloroquine decreases oral-caecal transit time.
    Adjepon-Yamoah KK; Woolhouse NM; Ofori-Adjei D; Nortey LN
    Br J Clin Pharmacol; 1985 Oct; 20(4):425-6. PubMed ID: 2866787
    [No Abstract]   [Full Text] [Related]  

  • 9. [Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)].
    Eitner K; Hippius M; Reinicke C
    Dtsch Z Verdau Stoffwechselkr; 1982; 42(1):14-9. PubMed ID: 6122556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-performance liquid chromatographic determination of aminosalicylate, sulfapyridine and their metabolites. Its application for pharmacokinetic studies with salicylazosulfapyridine in man.
    Fischer C; Klotz U
    J Chromatogr; 1979 Feb; 162(2):237-43. PubMed ID: 33196
    [No Abstract]   [Full Text] [Related]  

  • 11. A comparison of orocaecal transit times assessed by the breath hydrogen test and the sulphasalazine/sulphapyridine method in healthy beagle dogs.
    Papasouliotis K; Gruffydd-Jones TJ; Sparkes AH; Cripps PJ
    Res Vet Sci; 1995 May; 58(3):263-7. PubMed ID: 7659853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration.
    Shaffer JL; Houston JB
    Br J Clin Pharmacol; 1985 Apr; 19(4):526-8. PubMed ID: 2859874
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.
    Rahav G; Zylber-Katz E; Rachmilewitz D; Levy M
    Isr J Med Sci; 1990 Jan; 26(1):31-4. PubMed ID: 1968894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using pharmacokinetic modeling to determine the effect of drug and food on gastrointestinal transit in dogs.
    Sjödin L; Visser S; Al-Saffar A
    J Pharmacol Toxicol Methods; 2011; 64(1):42-52. PubMed ID: 21596146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of food on gastrointestinal transit of liquids in cynomolgus monkeys.
    Kondo H; Watanabe T; Yokohama S; Watanabe J
    Biopharm Drug Dispos; 2003 May; 24(4):141-51. PubMed ID: 12698497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous determination of sulfasalazine and its metabolites sulfapyridine and N-acetylsulfapyridine in human serum by ion-pair high-performance liquid chromatography using a polymer-based column.
    Buggé CJ; Gautam SR; Parke LE; Mason JT; Garcia DB
    J Pharm Sci; 1990 Dec; 79(12):1095-8. PubMed ID: 1981912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.
    Sharp ME; Wallace SM; Hindmarsh KW; Brown MA
    Eur J Clin Pharmacol; 1981; 21(3):243-50. PubMed ID: 6119205
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug.
    Fujioka Y; Metsugi Y; Ogawara K; Higaki K; Kimura T
    Int J Pharm; 2008 Mar; 352(1-2):36-43. PubMed ID: 18037251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of acetorphan, an antidiarrhoeal enkephalinase inhibitor, on oro-caecal and colonic transit times in healthy volunteers.
    Bergmann JF; Chaussade S; Couturier D; Baumer P; Schwartz JC; Lecomte JM
    Aliment Pharmacol Ther; 1992 Jun; 6(3):305-13. PubMed ID: 1350927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment].
    Guastavino E; Litwin NH; Heffes Nahmod L; Licastro R
    Acta Gastroenterol Latinoam; 1988; 18(2):107-13. PubMed ID: 2908013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.